Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
What role could emerging technologies, such as antimicrobial coatings or biofilm-disrupting agents, play in reducing the incidence of CIED infections?
Related Questions
For patients with candida species osteomyelitis who have undergone extensive surgical debridement, do you routinely still recommend 6-12 months of antifungal therapy or opt for a shorter duration?
Under what circumstance would you order dalbavancin instead of vancomycin or daptomycin for MRSA endocarditis?
Would you treat a brain abscess due to S. anginosus longer than one caused by another organism?
What would be an ideal time to place a VP shunt in a patient with candida meningitis/ventriculitis?
Are there situations where you would consider treating E faecalis or E faecium that grows from a respiratory culture?
What factors do you consider when choosing between baloxavir and oseltamivir for treating patients with influenza?
What is the recommended duration of therapy for Enterococcal bacteremia from a urinary source in patients with prosthetic valves assuming negative TEE and clearance of bacteremia?
Do you use first generation cephalosporins to treat non-endovascular streptococcus mitis infections?
Do you recommend immunomodulating treatments such as steroids or IVIG for West Nile Virus neuroinvasive disease?
How long do you treat Staphylococcus aureus pyomyositis with antibiotics?
